Celldex shares dinged after it redesigns PhIII cancer study; GenVec gains $3M milestone; AcelRx CEO preps an exit;

@FierceBiotech: Merck partners with Bind on a pair of new cancer drug programs. News | Follow @FierceBiotech

@JohnCFierce: Aeterna Zentaris bottoms out after a stinging FDA rejection--$AEZS down 51%. More | Follow @JohnCFierce

@DamianFierce: So $ABBV's not disclosing a PDUFA date for its HCV combo, but its June priority review disclosure puts in mid Dec. June release | Follow @DamianFierce

@EmilyMFierce: Glaxo hep C vaccine delivers promising early results. FierceVaccines story | Follow @EmilyMFierce

> Celldex Therapeutics reported that a slower-than-expected rate of patient recruitment forced it to change the Phase III design for glembatumumab (CDX-011), in development for triple negative breast cancer. The biotech's shares fell Wednesday evening before bounding back on Thursday. Story

> GenVec says it has picked up a $3 million milestone from Novartis. Release

> Redwood City, CA-based AcelRx says its CEO, Richard King, is leaving the company. He will stay on until a successor is found. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Medtronic in high spirits over positive study results for drug-coated balloon. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI yesterday: Government report says device tax will not deter innovation. Story | Follow @VarunSaxena2

@EmilyWFierce: ICYMI yesterday: Medtronic in high spirits over positive study results for drug-coated balloon. More | Follow @EmilyWFierce

> Dexcom snags FDA approval for next-gen artificial pancreas tech for blood glucose monitoring system. Report

> Stryker agrees to pay $1.43B to settle recalled hip implant lawsuits. Story

> Dozens of lawsuits filed in growing counterfeit spinal screw implant scandal. Article

Pharma News

@FiercePharma: Top-read in FiercePharmaMarketing Weds: Sanofi revamps 'underperforming' U.S. sales team under new diabetes chief. Article | Follow @FiercePharma

@EricPFierce: Boehringer Ingelheim unloads US API plant to Chinese company even as it expands in China. ICYMI from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: ICYMI: This week's FiercePharmaMarketing newsletter. Subscribe to get it weekly. | Follow @CarlyHFierce

> FDA yanks Ranbaxy's tentative approval for generic Nexium. Item

> Nexium reprieve lets AstraZeneca spend, spend, spend to prep for 2015 knockdown. Article

> Perrigo snaps up OTC specialist Omega in deal worth $5.7B. News

Pharma Manufacturing News

> Two more guilty pleas in spectacular burglary of Lilly warehouse. News

> Valeant labeling snafu affects Sanofi's Aplenzin, as well as Valeant's vaseretic. Report

> Ranbaxy manufacturing mess costs it exclusive for Valcyte generic. More

> Baxter spends $10M expanding admixing facility in Canada. Story

> German meat company invests $30M in plant for traceable heparin ingredients. Article

Vaccines News

> Inhaled Ebola vaccine may provide higher protection rate. News

> Sanofi, armed with more strong PhIII dengue data, sets sights on 2015 rollout. Report

> Glaxo hep C vaccine delivers promising early results. Story

> Sanofi, Protein Sciences win flu jab nods in older adults. Item

> PATH Malaria Vaccines Initiative nets $156M from Gates Foundation. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.